Home › Targets › CD33
Radioligand therapy target profile

CD33: IHC Expression in Cancer and Radioligand Target Profile

CD33 molecule · Ensembl ENSG00000105383 · Data updated 2026-11-16

CD33, CD33 molecule, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CD33 staining is highest in lymphoma (33% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality), with 1 active clinical trial.

Is CD33 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze CD33 free
LocalizationCell-Surface
Top cancer (IHC)Lymphoma
InternalizationNot assessed
Clinical stageClinical-stage (up to phase 3, any modality)
Active trials1
Cancer association (Open Targets)0.62

Is CD33 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

CD33 IHC staining by cancer type

Protein expression of CD33 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Lymphoma0.19Low33%

Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer, glioma, liver cancer.

Is CD33 internalized?

Nuclens has not yet extracted internalization evidence for CD33. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

CD33 clinical trials

Clinical-stage (up to phase 3, any modality). 1 active trial reference CD33 (ClinicalTrials.gov, accessed 2026-11-16).

NCT05672147

CD33 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CD33 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

CD33 gene essentiality (DepMap)

CRISPR knockout effect across 1252 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related lymphoma radioligand targets

c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD19 · CD45 (PTPRC) · SSTR2 · CD22 · STEAP2

See all radioligand therapy targets in lymphoma.

See how CD33 ranks against 15,000 targets for your indication.

Analyze CD33 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is CD33 the right target for your program? · 5 free analyses, no card Analyze CD33 free